[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338155-105":59,"doc-detail-338155-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","oncofetal-trim71-drives-liver-cancer-carcinogenesis-through-remodeling-cebpa-mediated-serineglycine-metabolism","Oncofetal TRIM71 drives liver cancer carcinogenesis through remodeling CEBPA-mediated serine/glycine metabolism","","Liver cancer cells remodel the transcriptome to build an oncofetal ecosystem that preserves stemness-like features, sustaining growth and extreme malignancy, yet the central regulators remain insufficiently defined. Using single-cell and bulk RNA-seq from fetal liver, normal tissue, tumors, and adjacent samples, investigators combined profiling with hydrodynamic mouse models to define oncofetal-related gene functions. Results show TRIM71 as a cancer-specific driver that stabilizes CEBPA mRNA via an IGF2BP1-m6A complex to enhance serine/glycine metabolism, while TRIM71 suppression or ATRA/EP300 inhibition reduces proliferation. The work highlights TRIM71 as a biomarker and therapeutic target.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/oncofetal-trim71-drives-liver-cancer-carcinogenesis-through-remodeling-cebpa-mediated-serineglycine-metabolism/338155/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/oncofetal-trim71-drives-liver-cancer-carcinogenesis-through-remodeling-cebpa-mediated-serineglycine-metabolism/338155.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the core research question about liver cancer in this paper?","Question",{"text":112,"@type":113},"The study seeks to identify regulatory drivers that enable liver cancer cells to adopt oncofetal characteristics and promote carcinogenesis and progression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were TRIM71’s functions investigated?",{"text":117,"@type":113},"The authors used single-cell and bulk RNA-seq datasets and established mouse models with hydrodynamic tail vein injection to test oncofetal-related oncogene functions, then performed mechanistic and knockdown experiments in liver cancer cells.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism does TRIM71 use to promote liver cancer?",{"text":121,"@type":113},"TRIM71 forms a complex with IGF2BP1, binds to and stabilizes CEBPA mRNA in an m6A-dependent manner, enhances the serine/glycine metabolic pathway, and drives tumor progression.",{"name":123,"@type":110,"acceptedAnswer":124},"What therapeutic strategies were evaluated in relation to TRIM71?",{"text":125,"@type":113},"All-trans-retinoic acid (ATRA) combined with an EP300 inhibitor (A-485) repressed TRIM71, reduced glycine/serine metabolism, and inhibited liver cancer cell proliferation, particularly when TRIM71 levels were high.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},338155,1791296621,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Ivyspring  \nInternational Publisher  \nTheranostics  \n2024; 14(13): 4948-4966. doi: 10.7150/thno.99633  \nResearch Paper  \nOncofetal TRIM71 drives liver cancer carcinogenesis through remodeling CEBPA-mediated serine/glycine metabolism  \nYing Su1,2,*, Ziteng Li2,*, Qin Li2,*, Xinyi Guo1,2, Hena Zhang1,2, Yan Li1,2, Zhiqiang Meng1,2,􀀍, Shenglin Huang1,2,􀀍, Zhixiang Hu1,2,􀀍  \n1. Department of Integrative Oncology, Fudan University Shanghai Cancer Center, and Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.  \n2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.  \n* These authors contributed equally to this work.  \n􀀍 Corresponding authors: Zhixiang Hu, Ph.D., Email: [zhixiang_hu@fudan.edu.cn](zhixiang_hu@fudan.edu.cn); Shenglin Huang, Ph.D., Email: [slhuang@fudan.edu.cn](slhuang@fudan.edu.cn); or Zhiqiang Meng, M.D., [Email: mengshca@fudan.edu.cn. Department](Email: mengshca@fudan.edu.cn. Department) of Integrative Oncology, Fudan University Shanghai Cancer Center, and Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, 305 Rm., 7\\# Bldg., 270 Dong An Rd., Shanghai, 200032, China.  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [http://ivyspring.com/terms](http://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2024.06.14; Accepted: 2024.08.07; Published: 2024.08.12  \nAbstract  \nRationale: Tumor cells remodel transcriptome to construct an ecosystem with stemness features, which maintains tumor growth and highly malignant characteristics. However, the core regulatory factors involved in this process still need to be further discovered.  \nMethods: Single cell RNA-sequncing (scRNA-seq) and bulk RNA-sequencing profiles derived from fetal liver, normal liver, liver tumors, and their adjacent samples were collected to analyze the ecosystem of liver cancer. Mouse models were established to identify molecular functions of oncofetal-related oncogenes using hydrodynamic tail vein injection.  \nResults: We found that liver cancer rebuilt oncofetal ecosystem to maintain malignant features. Interestingly, we identified a group of RNA-binding proteins (RBPs) that were highly overexpressed with oncofetal features. Among them, TRIM71 was specifically expressed in liver cancers and was associated with poor outcomes. TRIM71 drove the carcinogenesis of hepatocellular carcinoma ( HCC), and knockdown of TRIM71 significantly abolished liver cancer cell proliferation. Mechanistically, TRIM71 formed a protein complex with IGF2BP1, bound to and stabilized the mRNA of CEBPA in an m6A-dependent manner, enhance the serine/glycine metabolic pathway, and ultimately promoted liver cancer progression. Furthermore, we identified that all-trans-retinoic acid (ATRA) combined with e1A binding protein p300 (EP300) inhibitor A-485 repressed TRIM71, attenuated glycine/serine metabolism, and inhibited liver cancer cell proliferation with high TRIM71 levels.  \nConclusions: We demonstrated the oncofetal status in liver cancer and highlighted the crucial role of TRIM71 and provided potential therapeutic strategies and liver cancer-specific biomarker for liver cancer patients.  \nKeywords: RNA-binding proteins; TRIM71; CEBPA; m6A; serine/glycine metabolism  \nIntroduction  \nThe central concept of cancer development is that cancer cells acquire multiple cellular properties known as cancer hallmarks, including deregulating cellular metabolism and undergoing non-mutational  \nepigenetic reprogramming [1] . This phenomenon is more prevalent in low-mutant cancers such","cbCaiqhtUDa7ZhYm","https://ap.wps.com/l/cbCaiqhtUDa7ZhYm","pdf",11401932,"English","# Abstract\n## Rationale\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is the core research question about liver cancer in this paper?\",\"answer\":\"The study seeks to identify regulatory drivers that enable liver cancer cells to adopt oncofetal characteristics and promote carcinogenesis and progression.\"},{\"question\":\"How were TRIM71’s functions investigated?\",\"answer\":\"The authors used single-cell and bulk RNA-seq datasets and established mouse models with hydrodynamic tail vein injection to test oncofetal-related oncogene functions, then performed mechanistic and knockdown experiments in liver cancer cells.\"},{\"question\":\"What mechanism does TRIM71 use to promote liver cancer?\",\"answer\":\"TRIM71 forms a complex with IGF2BP1, binds to and stabilizes CEBPA mRNA in an m6A-dependent manner, enhances the serine/glycine metabolic pathway, and drives tumor progression.\"},{\"question\":\"What therapeutic strategies were evaluated in relation to TRIM71?\",\"answer\":\"All-trans-retinoic acid (ATRA) combined with an EP300 inhibitor (A-485) repressed TRIM71, reduced glycine/serine metabolism, and inhibited liver cancer cell proliferation, particularly when TRIM71 levels were high.\"}]","Oncofetal TRIM71 drives liver cancer carcinogenesis through remodeling CEBPA-mediated serine/glycine metabolism | PDF",1790022260,48,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/789689baad950982d9535b4b06b150e9.webp",983,1272,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d7878c6cfdca76a7d5c70d8089455488.webp",982,1270,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3156d978c63b8853e4d3bb9987a18b1.webp",981,1269,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/554fe9732d6e22da5d3494ec6854885c.webp",980,1268]